<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34575995</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>18</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Current Concepts on Genetic Aspects of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9832</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22189832</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS), neurodegenerative motor neuron disorder is characterized as multisystem disease with important contribution of genetic factors. The etiopahogenesis of ALS is not fully elucidate, but the dominant theory at present relates to RNA processing, as well as protein aggregation and miss-folding, oxidative stress, glutamate excitotoxicity, inflammation and epigenetic dysregulation. Additionally, as mitochondria plays a leading role in cellular homeostasis maintenance, a rising amount of evidence indicates mitochondrial dysfunction as a substantial contributor to disease onset and progression. The aim of this review is to summarize most relevant findings that link genetic factors in ALS pathogenesis with different mechanisms with mitochondrial involvement (respiratory chain, OXPHOS control, calcium buffering, axonal transport, inflammation, mitophagy, etc.). We highlight the importance of a widening perspective for better understanding overlapping pathophysiological pathways in ALS and neurodegeneration in general. Finally, current and potentially novel therapies, especially gene specific therapies, targeting mitochondrial dysfunction are discussed briefly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Milena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3939-9739</Identifier><AffiliationInfo><Affiliation>Neurology Clinic, Clinical Center of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novakovic</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamil Anwar Dawod</LastName><ForeName>Phepy</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, 11591 Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamil Anwar Dawod</LastName><ForeName>Ayman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine, Hepatogastroenterology and Endoscopy Department, Faculty of Medicine, Ain Shams University, 11591 Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drinic</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel Motaleb</LastName><ForeName>Fayda I</ForeName><Initials>FI</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, 11591 Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducic</LastName><ForeName>Sinisa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Surgery Department, University Children's Hospital, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolic</LastName><ForeName>Dejan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0609-9916</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Physical Medicine and Rehabilitation Department, University Children's Hospital, Tirsova 10, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004579" MajorTopicYN="N">Electron Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="Y">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063306" MajorTopicYN="N">Mitophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">genes</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>Authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34575995</ArticleId><ArticleId IdType="pmc">PMC8469731</ArticleId><ArticleId IdType="doi">10.3390/ijms22189832</ArticleId><ArticleId IdType="pii">ijms22189832</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brotman R.G., Moreno-Escobar M.C., Joseph J., Pawar G. StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2021. Amyotrophic Lateral Sclerosis.</Citation></Reference><Reference><Citation>Logroscino G., Piccininni M. Amyotrophic Lateral Sclerosis Descriptive Epidemiology: The Origin of Geographic Difference. Neuroepidemiology. 2019;52:93&#x2013;103. doi: 10.1159/000493386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000493386</ArticleId><ArticleId IdType="pubmed">30602169</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F., Silani V., Otto M. Neurochemical biomarkers in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2019;32:747&#x2013;757. doi: 10.1097/WCO.0000000000000744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000744</ArticleId><ArticleId IdType="pubmed">31403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S., Stauffer J.E., Schulte D.J., Ravits J. Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol. Clin. 2015;33:855&#x2013;876. doi: 10.1016/j.ncl.2015.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.012</ArticleId><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E., Fang F. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr. Opin. Neurol. 2019;32:771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadena K., Vlamos P. Amyotrophic Lateral Sclerosis: Current Status in Diagnostic Biomarkers. Adv. Exp. Med. Biol. 2020;1195:179&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">32468476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S., Orrell R.W. Pathogenesis of amyotrophic lateral sclerosis. Br. Med. Bull. 2016;119:87&#x2013;98. doi: 10.1093/bmb/ldw026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bmb/ldw026</ArticleId><ArticleId IdType="pubmed">27450455</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly Z.R., Scott K.M., Abhinav K., Wijesekera L., Ganesalingam J., Goldstein L.H., Janssen A., Dougherty A., Willey E., Stanton B.R., et al. The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotroph. Lateral Scler. 2010;11:439&#x2013;442. doi: 10.3109/17482961003610853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003610853</ArticleId><ArticleId IdType="pmc">PMC6485484</ArticleId><ArticleId IdType="pubmed">20225930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Logroscino G., Traynor B.J., Collins J., Simeone J.C., Goldstein L.A., White L.A. Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature. Neuroepidemiology. 2013;41:118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulisz D. Amyotrophic lateral sclerosis: Disease state overview. Am. J. Manag. Care. 2018;24((Suppl. 15)):S320&#x2013;S326.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207670</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris S.P., Likanje M.N., Andrews J.A. Amyotrophic lateral sclerosis: Update on clinical management. Curr. Opin. Neurol. 2020;33:641&#x2013;648. doi: 10.1097/WCO.0000000000000864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000864</ArticleId><ArticleId IdType="pubmed">32868602</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B., Gendron T.F., Staff N.P. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin. Proc. 2018;93:1617&#x2013;1628. doi: 10.1016/j.mayocp.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Valko K., Ciesla L. Amyotrophic lateral sclerosis. Prog. Med. Chem. 2019;58:63&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">30879475</ArticleId></ArticleIdList></Reference><Reference><Citation>Tard C., Defebvre L., Moreau C., Devos D., Danel-Brunaud V. Clinical features of amyotrophic lateral sclerosis and their prognostic value. Rev. Neurol. 2017;173:263&#x2013;272. doi: 10.1016/j.neurol.2017.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.03.029</ArticleId><ArticleId IdType="pubmed">28477850</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T., Kitagawa K., Arai K. Phenotypic variability and its pathological basis in amyotrophic lateral sclerosis. Neuropathology. 2020;40:40&#x2013;56. doi: 10.1111/neup.12606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12606</ArticleId><ArticleId IdType="pubmed">31802540</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S., Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2007;66:10&#x2013;16. doi: 10.1097/nen.0b013e31802c396b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31802c396b</ArticleId><ArticleId IdType="pubmed">17204932</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Lumbroso S., Cazeneuve C., Mouzat K., Camu W., Vourc&#x2019;h P., on Behalf the FILSLAN network Pre-symptomatic diagnosis in ALS. Rev. Neurol. 2020;176:166&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">31932031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan R., Haque S., Coley K., Shepheard S., Cooper-Knock J., Kirby J. Multifaceted Genes in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia. Front. Neurosci. 2020;14:684. doi: 10.3389/fnins.2020.00684.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00684</ArticleId><ArticleId IdType="pmc">PMC7358438</ArticleId><ArticleId IdType="pubmed">32733193</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405&#x2013;424. doi: 10.1038/gim.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Marangi G., Doronzio P.N., Conte A., Bisogni G., Zollino M., Sabatelli M. High-Throughput Genetic Testing in ALS: The Challenging Path of Variant Classification Considering the ACMG Guidelines. Genes. 2020;11:1123. doi: 10.3390/genes11101123.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes11101123</ArticleId><ArticleId IdType="pmc">PMC7600768</ArticleId><ArticleId IdType="pubmed">32987860</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt J.H., Hyman T., Dikic I. Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Trends Mol. Med. 2016;22:769&#x2013;783. doi: 10.1016/j.molmed.2016.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2016.07.005</ArticleId><ArticleId IdType="pubmed">27498188</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzuti A., Petrucci S. Mitochondrial disfunction as a cause of ALS. Arch. Ital. Biol. 2011;149:113&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">21412720</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho B., Choi S.Y., Cho H.M., Kim H.J., Sun W. Physiological and pathological significance of dynamin-related protein 1 (drp1)-dependent mitochondrial fission in the nervous system. Exp. Neurobiol. 2013;22:149&#x2013;157. doi: 10.5607/en.2013.22.3.149.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2013.22.3.149</ArticleId><ArticleId IdType="pmc">PMC3807002</ArticleId><ArticleId IdType="pubmed">24167410</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Yamashita T., Tian F., Morimoto N., Ikeda Y., Deguchi K., Abe K. Mitochondrial fusion and fission proteins expression dynamically change in a murine model of amyotrophic lateral sclerosis. Curr. Neurovasc. Res. 2013;10:222&#x2013;230. doi: 10.2174/15672026113109990060.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/15672026113109990060</ArticleId><ArticleId IdType="pubmed">23713734</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.Y., Lee J.H., Chung A.Y., Jo Y., Shin J.H., Park H.C., Kim H., Lopez-Gonzalez R., Ryu J.R., Sun W. Prevention of mitochondrial impairment by inhibition of protein phosphatase 1 activity in amyotrophic lateral sclerosis. Cell Death Dis. 2020;11:888. doi: 10.1038/s41419-020-03102-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03102-8</ArticleId><ArticleId IdType="pmc">PMC7578657</ArticleId><ArticleId IdType="pubmed">33087694</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangaraju V., Lauterbach M., Schuman E.M. Spatially stable mitochondrial compartments fuel local translation during plasticity. Cell. 2019;176:73&#x2013;84.e15. doi: 10.1016/j.cell.2018.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.12.013</ArticleId><ArticleId IdType="pubmed">30612742</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi P., Wei Y., Zhang J., Gal J., Zhu H. Mitochondrial dysfunction is a converging point of multiple pathological pathways in amyotrophic lateral sclerosis. J. Alzheimers. Dis. 2010;20((Suppl. 2)):S311&#x2013;S324. doi: 10.3233/JAD-2010-100366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-100366</ArticleId><ArticleId IdType="pubmed">20463400</ArticleId></ArticleIdList></Reference><Reference><Citation>Borthwick G.M., Johnson M.A., Ince P.G., Shaw P.J., Turnbull D.M. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: Implications for the role of mitochondria in neuronal cell death. Ann. Neurol. 1999;46:787&#x2013;790. doi: 10.1002/1531-8249(199911)46:5&lt;787::AID-ANA17&gt;3.0.CO;2-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199911)46:5&lt;787::AID-ANA17&gt;3.0.CO;2-8</ArticleId><ArticleId IdType="pubmed">10553999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P., Sampath H. Mitochondrial DNA Integrity: Role in Health and Disease. Cells. 2019;8:100. doi: 10.3390/cells8020100.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8020100</ArticleId><ArticleId IdType="pmc">PMC6406942</ArticleId><ArticleId IdType="pubmed">30700008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakahira K., Haspel J.A., Rathinam V.A., Lee S.J., Dolinay T., Lam H.C., Englert J.A., Rabinovitch M., Cernadas M., Kim H.P., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 2011;12:222&#x2013;230. doi: 10.1038/ni.1980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1980</ArticleId><ArticleId IdType="pmc">PMC3079381</ArticleId><ArticleId IdType="pubmed">21151103</ArticleId></ArticleIdList></Reference><Reference><Citation>West A.P., Khoury-Hanold W., Staron M., Tal M.C., Pineda C.M., Lang S.M., Bestwick M., Duguay B.A., Raimundo N., MacDuff D.A., et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015;520:553&#x2013;557. doi: 10.1038/nature14156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14156</ArticleId><ArticleId IdType="pmc">PMC4409480</ArticleId><ArticleId IdType="pubmed">25642965</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoccoro A., Mosca L., Carnicelli V., Cavallari U., Lunetta C., Marocchi A., Migliore L., Copped&#xe8; F. Mitochondrial DNA copy number and D-loop region methylation in carriers of amyotrophic lateral sclerosis gene mutations. Epigenomics. 2018;10:1431&#x2013;1443. doi: 10.2217/epi-2018-0072.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/epi-2018-0072</ArticleId><ArticleId IdType="pubmed">30088417</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoccoro A., Smith A.R., Mosca L., Marocchi A., Gerardi F., Lunetta C., Cereda C., Gagliardi S., Lunnon K., Migliore L., et al. Reduced mitochondrial D-loop methylation levels in sporadic amyotrophic lateral sclerosis. Clin. Epigenetics. 2020;12:137. doi: 10.1186/s13148-020-00933-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-020-00933-2</ArticleId><ArticleId IdType="pmc">PMC7488473</ArticleId><ArticleId IdType="pubmed">32917270</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0. Erratum in 1993, 364, 362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G., Gautier O., Tassoni-Tsuchida E., Ma X.R., Gitler A.D. ALS Genetics: Gains, Losses, and Implications for Future Therapies. Neuron. 2020;108:822&#x2013;842. doi: 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunton-Stasyshyn R.K., Saccon R.A., Fratta P., Fisher E.M. SOD1 Function and Its Implications for Amyotrophic Lateral Sclerosis Pathology: New and Renascent Themes. Neuroscientist. 2015;21:519&#x2013;529. doi: 10.1177/1073858414561795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858414561795</ArticleId><ArticleId IdType="pubmed">25492944</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickles S., Destroismaisons L., Peyrard S.L., Cadot S., Rouleau G.A., Brown R.H., Jr., Julien J.P., Arbour N., Vande Velde C. Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum. Mol. Genet. 2013;22:3947&#x2013;3959. doi: 10.1093/hmg/ddt249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt249</ArticleId><ArticleId IdType="pmc">PMC5052069</ArticleId><ArticleId IdType="pubmed">23736301</ArticleId></ArticleIdList></Reference><Reference><Citation>Tak Y.J., Park J.H., Rhim H., Kang S. ALS-Related Mutant SOD1 Aggregates Interfere with Mitophagy by Sequestering the Autophagy Receptor Optineurin. Int. J. Mol. Sci. 2020;21:7525. doi: 10.3390/ijms21207525.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21207525</ArticleId><ArticleId IdType="pmc">PMC7590160</ArticleId><ArticleId IdType="pubmed">33065963</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyers J., Banchi E.G., Latouche M. C9ORF72: What It Is, What It Does, and Why It Matters. Front. Cell. Neurosci. 2021;15:661447. doi: 10.3389/fncel.2021.661447.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.661447</ArticleId><ArticleId IdType="pmc">PMC8131521</ArticleId><ArticleId IdType="pubmed">34025358</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C.N., Wu Y., Odeh H.M., Gendron T.F., Jansen-West K., Del Rosso G., Yue M., Jiang P., Gomes E., Tong J., et al. C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci. Transl. Med. 2020;12:eabb3774. doi: 10.1126/scitranslmed.abb3774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abb3774</ArticleId><ArticleId IdType="pmc">PMC7989020</ArticleId><ArticleId IdType="pubmed">32878979</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesto E., Colombrita C., Gumina V., Borghi M.O., Dusi S., Doretti A., Fagiolari G., Invernizzi F., Moggio M., Tiranti V., et al. Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. Acta Neuropathol. Commun. 2016;4:47. doi: 10.1186/s40478-016-0316-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0316-5</ArticleId><ArticleId IdType="pmc">PMC4858818</ArticleId><ArticleId IdType="pubmed">27151080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Lu Y., Gendron T.F., Karydas A., Tran H., Yang D., Petrucelli L., Miller B.L., Almeida S., Gao F.B. Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron. 2016;92:383&#x2013;391. doi: 10.1016/j.neuron.2016.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Wu Z., Tantray I., Li Y., Chen S., Dong J., Glynn S., Vogel H., Snyder M., Lu B. Quality-control mechanisms targeting translationally stalled and C-terminally extended poly(GR) associated with ALS/FTD. Proc. Natl. Acad. Sci. USA. 2020;117:25104&#x2013;25115. doi: 10.1073/pnas.2005506117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2005506117</ArticleId><ArticleId IdType="pmc">PMC7547246</ArticleId><ArticleId IdType="pubmed">32958650</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R., Barbagallo P., Farrimond L., Candalija A., Scaber J., Ababneh N.A., Sathyaprakash C., Vowles J., Cowley S.A., Talbot K. Impairment of Mitochondrial Calcium Buffering Links Mutations in C9ORF72 and TARDBP in iPS-Derived Motor Neurons from Patients with ALS/FTD. Stem Cell Rep. 2020;14:892&#x2013;908. doi: 10.1016/j.stemcr.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.03.023</ArticleId><ArticleId IdType="pmc">PMC7220989</ArticleId><ArticleId IdType="pubmed">32330447</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R., Barbagallo P., Talbot K. The Role of Mitochondrial Dysfunction and ER Stress in TDP-43 and C9ORF72 ALS. Front. Cell. Neurosci. 2021;15:653688. doi: 10.3389/fncel.2021.653688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.653688</ArticleId><ArticleId IdType="pmc">PMC8047135</ArticleId><ArticleId IdType="pubmed">33867942</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A.R., Gregory J.M., Dando O., Carter R.N., Burr K., Nanda J., Story D., McDade K., Smith C., Morton N.M., et al. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol. 2021;141:257&#x2013;279. doi: 10.1007/s00401-020-02252-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02252-5</ArticleId><ArticleId IdType="pmc">PMC7847443</ArticleId><ArticleId IdType="pubmed">33398403</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T., Liu H., Itoh K., Oh S., Zhao L., Murata D., Sesaki H., Hartung T., Na C.H., Wang J. C9orf72 regulates energy homeostasis by stabilizing mitochondrial complex I assembly. Cell. Metab. 2021;33:531&#x2013;546.e9. doi: 10.1016/j.cmet.2021.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.01.005</ArticleId><ArticleId IdType="pubmed">33545050</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.Y., Lopez-Gonzalez R., Krishnan G., Phillips H.L., Li A.N., Seeley W.W., Yao W.D., Almeida S., Gao F.B. C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nat. Neurosci. 2019;22:851&#x2013;862. doi: 10.1038/s41593-019-0397-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0397-0</ArticleId><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="pubmed">31086314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Yang B., Zhang D. Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. Glia. 2011;59:946&#x2013;958. doi: 10.1002/glia.21167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21167</ArticleId><ArticleId IdType="pmc">PMC3077460</ArticleId><ArticleId IdType="pubmed">21446050</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V., Phaneuf D., Dupr&#xe9; N., Petri S., Strong M., Kriz J., Julien J.P. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor &#x3ba;B-mediated pathogenic pathways. J. Exp. Med. 2011;208:2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucini C.B., Braun R.J. Mitochondrion-Dependent Cell Death in TDP-43 Proteinopathies. Biomedicines. 2021;9:376. doi: 10.3390/biomedicines9040376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9040376</ArticleId><ArticleId IdType="pmc">PMC8066287</ArticleId><ArticleId IdType="pubmed">33918437</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.H., Davidson S., Harapas C.R., Hilton J.B., Mlodzianoski M.J., Laohamonthonkul P., Louis C., Low R.R.J., Moecking J., De Nardo D., et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020;183:636&#x2013;649.e18. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q., Sun L., Chen Z.J. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 2016;17:1142&#x2013;1149. doi: 10.1038/ni.3558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3558</ArticleId><ArticleId IdType="pubmed">27648547</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa H., Barber G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455:674&#x2013;678. doi: 10.1038/nature07317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07317</ArticleId><ArticleId IdType="pmc">PMC2804933</ArticleId><ArticleId IdType="pubmed">18724357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliter D.A., Martinez J., Hao L., Chen X., Sun N., Fischer T.D., Burman J.L., Li Y., Zhang Z., Narendra D.P., et al. Parkin and PINK1 mitigate STING-induced inflammation. Nature. 2018;561:258&#x2013;262. doi: 10.1038/s41586-018-0448-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0448-9</ArticleId><ArticleId IdType="pmc">PMC7362342</ArticleId><ArticleId IdType="pubmed">30135585</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D., Rodde R., Edbauer D., Bentmann E., Fischer I., Hruscha A., Than M.E., Mackenzie I.R., Capell A., Schmid B., et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010;29:2841&#x2013;2857. doi: 10.1038/emboj.2010.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.143</ArticleId><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai Y.L., Coady T.H., Lu L., Zheng D., Alland I., Tian B., Shneider N.A., Manley J.L. ALS/FTD-associated protein FUS induces mitochondrial dysfunction by preferentially sequestering respiratory chain complex mRNAs. Genes Dev. 2020;34:785&#x2013;805. doi: 10.1101/gad.335836.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.335836.119</ArticleId><ArticleId IdType="pmc">PMC7263147</ArticleId><ArticleId IdType="pubmed">32381627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho W.Y., Agrawal I., Tyan S.H., Sanford E., Chang W.T., Lim K., Ong J., Tan B.S.Y., Moe A.A.K., Yu R., et al. Dysfunction in nonsense-mediated decay, protein homeostasis, mitochondrial function, and brain connectivity in ALS-FUS mice with cognitive deficits. Acta Neuropathol. Commun. 2021;9:9. doi: 10.1186/s40478-020-01111-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01111-4</ArticleId><ArticleId IdType="pmc">PMC7789430</ArticleId><ArticleId IdType="pubmed">33407930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Bassot A., Giuliani F., Simmen T. Amyotrophic Lateral Sclerosis (ALS): Stressed by Dysfunctional Mitochondria-Endoplasmic Reticulum Contacts (MERCs) Cells. 2021;10:1789. doi: 10.3390/cells10071789.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10071789</ArticleId><ArticleId IdType="pmc">PMC8304209</ArticleId><ArticleId IdType="pubmed">34359958</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Simmen T. Mechanistic Connections between Endoplasmic Reticulum (ER) Redox Control and Mitochondrial Metabolism. Cells. 2019;8:1071. doi: 10.3390/cells8091071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8091071</ArticleId><ArticleId IdType="pmc">PMC6769559</ArticleId><ArticleId IdType="pubmed">31547228</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura A.L., Mitne-Neto M., Silva H.C., Richieri-Costa A., Middleton S., Cascio D., Kok F., Oliveira J.R., Gillingwater T., Webb J., et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 2004;75:822&#x2013;831. doi: 10.1086/425287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/425287</ArticleId><ArticleId IdType="pmc">PMC1182111</ArticleId><ArticleId IdType="pubmed">15372378</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi P., Guo H., Dreser A., Yamoah A., Sechi A., Jesse C.M., Katona I., Doukas P., Nikolin S., Ernst S., et al. Pathomechanisms of ALS8: Altered autophagy and defective RNA binding protein (RBP) homeostasis due to the VAPB P56S mutation. Cell Death Dis. 2021;12:466. doi: 10.1038/s41419-021-03710-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-03710-y</ArticleId><ArticleId IdType="pmc">PMC8110809</ArticleId><ArticleId IdType="pubmed">33972508</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho M.A., Strider J., Carter D., Taylor-Reinwald L., Forman M.S., Goate A.M., Cairns N.J. VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death. J. Biol. Chem. 2009;284:12384&#x2013;12398. doi: 10.1074/jbc.M900992200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M900992200</ArticleId><ArticleId IdType="pmc">PMC2673306</ArticleId><ArticleId IdType="pubmed">19237541</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.O., Mandrioli J., Benatar M., Abramzon Y., Van Deerlin V.M., Trojanowski J.Q., Gibbs J.R., Brunetti M., Gronka S., Wuu J., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857&#x2013;864. doi: 10.1016/j.neuron.2010.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.036</ArticleId><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N.C., Tresse E., Kolaitis R.M., Molliex A., Thomas R.E., Alami N.H., Wang B., Joshi A., Smith R.B., Ritson G.P., et al. VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations. Neuron. 2013;78:65&#x2013;80. doi: 10.1016/j.neuron.2013.02.029. Erratum in 2013, 78, 403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.029</ArticleId><ArticleId IdType="pmc">PMC3683300</ArticleId><ArticleId IdType="pubmed">23498974</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore A.S., Holzbaur E.L. Dynamic recruitment and activation of ALS-associated TBK1 with its target optineurin are required for efficient mitophagy. Proc. Natl. Acad. Sci. USA. 2016;113:E3349&#x2013;E3358. doi: 10.1073/pnas.1523810113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1523810113</ArticleId><ArticleId IdType="pmc">PMC4914160</ArticleId><ArticleId IdType="pubmed">27247382</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Lasseigne B.N., Petrovski S., Sapp P.C., Dion P.A., Leblond C.S., Couthouis J., Lu Y.F., Wang Q., Krueger B.J., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., M&#xfc;ller K., Marroquin N., Nordin F., H&#xfc;bers A., Weydt P., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong Y.C., Holzbaur E.L. Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proc. Natl. Acad. Sci. USA. 2014;111:E4439&#x2013;E4448. doi: 10.1073/pnas.1405752111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1405752111</ArticleId><ArticleId IdType="pmc">PMC4210283</ArticleId><ArticleId IdType="pubmed">25294927</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F., Yan J., Vemula S.P., Liu E., Yang Y., Chen W., Zheng J.G., Shi Y., Siddique N., Arrat H., et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2011;68:1440&#x2013;1446. doi: 10.1001/archneurol.2011.250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.250</ArticleId><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Layfield R., Hocking L.J. SQSTM1 and Paget&#x2019;s disease of bone. Calcif. Tissue Int. 2004;75:347&#x2013;357. doi: 10.1007/s00223-004-0041-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00223-004-0041-0</ArticleId><ArticleId IdType="pubmed">15365659</ArticleId></ArticleIdList></Reference><Reference><Citation>Haack T.B., Ignatius E., Calvo-Garrido J., Iuso A., Isohanni P., Maffezzini C., L&#xf6;nnqvist T., Suomalainen A., Gorza M., Kremer L.S., et al. Absence of the Autophagy Adaptor SQSTM1/p62 Causes Childhood-Onset Neurodegeneration with Ataxia, Dystonia, and Gaze Palsy. Am. J. Hum. Genet. 2016;99:735&#x2013;743. doi: 10.1016/j.ajhg.2016.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.06.026</ArticleId><ArticleId IdType="pmc">PMC5010644</ArticleId><ArticleId IdType="pubmed">27545679</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster A.D., Rea S.L. The role of sequestosome 1/p62 protein in amyotrophic lateral sclerosis and frontotemporal dementia pathogenesis. Neural Regen Res. 2020;15:2186&#x2013;2194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749485</ArticleId><ArticleId IdType="pubmed">32594029</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M., Jara J.H., Sekerkova G., Yasvoina M.V., Martina M., &#xd6;zdinler P.H. Absence of alsin function leads to corticospinal motor neuron vulnerability via novel disease mechanisms. Hum. Mol. Genet. 2016;25:1074&#x2013;1087. doi: 10.1093/hmg/ddv631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv631</ArticleId><ArticleId IdType="pmc">PMC4764190</ArticleId><ArticleId IdType="pubmed">26755825</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Hentati A., Deng H.X., Dabbagh O., Sasaki T., Hirano M., Hung W.Y., Ouahchi K., Yan J., Azim A.C., et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 2001;29:160&#x2013;165. doi: 10.1038/ng1001-160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1001-160</ArticleId><ArticleId IdType="pubmed">11586297</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S., Hand C.K., Osuga H., Yanagisawa Y., Otomo A., Devon R.S., Miyamoto N., Showguchi-Miyata J., Okada Y., Singaraja R., et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 2001;29:166&#x2013;173. doi: 10.1038/ng1001-166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1001-166</ArticleId><ArticleId IdType="pubmed">11586298</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Saif A., Al-Mohanna F., Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol. 2011;70:913&#x2013;919. doi: 10.1002/ana.22534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22534</ArticleId><ArticleId IdType="pubmed">21842496</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Ilieva H., Tamada H., Nomura H., Komine O., Endo F., Jin S., Mancias P., Kiyama H., Yamanaka K. Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR1- and SOD1-linked ALS. EMBO Mol. Med. 2016;8:1421&#x2013;1437. doi: 10.15252/emmm.201606403.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606403</ArticleId><ArticleId IdType="pmc">PMC5167132</ArticleId><ArticleId IdType="pubmed">27821430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth S., Ait-El-Mkadem S., Chaussenot A., Genin E.C., Lacas-Gervais S., Fragaki K., Berg-Alonso L., Kageyama Y., Serre V., Moore D.G., et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Pt 8Brain. 2014;137:2329&#x2013;2345. doi: 10.1093/brain/awu138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu138</ArticleId><ArticleId IdType="pmc">PMC4107737</ArticleId><ArticleId IdType="pubmed">24934289</ArticleId></ArticleIdList></Reference><Reference><Citation>Straub I.R., Weraarpachai W., Shoubridge E.A. Multi-OMICS study of a CHCHD10 variant causing ALS demonstrates metabolic rewiring and activation of endoplasmic reticulum and mitochondrial unfolded protein responses. Hum. Mol. Genet. 2021;30:687&#x2013;705. doi: 10.1093/hmg/ddab078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddab078</ArticleId><ArticleId IdType="pmc">PMC8127406</ArticleId><ArticleId IdType="pubmed">33749723</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C., Schludi M.H., Ransom L., Greiling J., Jungh&#xe4;nel M., Exner N., Riemenschneider H., van der Zee J., Van Broeckhoven C., Weydt P., et al. A novel CHCHD10 mutation implicates a Mia40-dependent mitochondrial import deficit in ALS. EMBO Mol. Med. 2018;10:e8558. doi: 10.15252/emmm.201708558.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201708558</ArticleId><ArticleId IdType="pmc">PMC5991575</ArticleId><ArticleId IdType="pubmed">29789341</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo J.A., Liu T., Trotter C., Fang C.C., De Narvaez E., LePochat P., Maslar D., Bukhari A., Zhao X., Deonarine A., et al. Loss of function CHCHD10 mutations in cytoplasmic TDP-43 accumulation and synaptic integrity. Nat. Commun. 2017;8:15558. doi: 10.1038/ncomms15558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15558</ArticleId><ArticleId IdType="pmc">PMC5467170</ArticleId><ArticleId IdType="pubmed">28585542</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., Yilmaz R., M&#xfc;ller K., Grehl T., Petri S., Meyer T., Grosskreutz J., Weydt P., Ruf W., Neuwirth C., et al. Hot-spot KIF5A mutations cause familial ALS. Brain. 2018;141:688&#x2013;697. doi: 10.1093/brain/awx370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx370</ArticleId><ArticleId IdType="pmc">PMC5837483</ArticleId><ArticleId IdType="pubmed">29342275</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A., Kenna K.P., Renton A.E., Ticozzi N., Faghri F., Chia R., Dominov J.A., Kenna B.J., Nalls M.A., Keagle P., et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 2018;97:1268&#x2013;1283.e6. doi: 10.1016/j.neuron.2018.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Duis J., Dean S., Applegate C., Harper A., Xiao R., He W., Dollar J.D., Sun L.R., Waberski M.B., Crawford T.O., et al. KIF5A mutations cause an infantile onset phenotype including severe myoclonus with evidence of mitochondrial dysfunction. Ann. Neurol. 2016;80:633&#x2013;637. doi: 10.1002/ana.24744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24744</ArticleId><ArticleId IdType="pmc">PMC5042851</ArticleId><ArticleId IdType="pubmed">27463701</ArticleId></ArticleIdList></Reference><Reference><Citation>Konovalova J., Gerasymchuk D., Parkkinen I., Chmielarz P., Domanskyi A. Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases. Int. J. Mol. Sci. 2019;20:6055. doi: 10.3390/ijms20236055.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20236055</ArticleId><ArticleId IdType="pmc">PMC6929013</ArticleId><ArticleId IdType="pubmed">31801298</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschrafi A., Kar A.N., Natera-Naranjo O., MacGibeny M.A., Gioio A.E., Kaplan B.B. MicroRNA-338 regulates the axonal expression of multiple nuclear-encoded mitochondrial mRNAs encoding subunits of the oxidative phosphorylation machinery. Cell Mol. Life Sci. 2012;69:4017&#x2013;4027. doi: 10.1007/s00018-012-1064-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-012-1064-8</ArticleId><ArticleId IdType="pubmed">22773120</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz A.R., Vizinha D., Morais H., Cola&#xe7;o A.R., Loch-Neckel G., Barbosa M., Brites D. Overexpression of miR-124 in Motor Neurons Plays a Key Role in ALS Pathological Processes. Int. J. Mol. Sci. 2021;22:6128. doi: 10.3390/ijms22116128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22116128</ArticleId><ArticleId IdType="pmc">PMC8201298</ArticleId><ArticleId IdType="pubmed">34200161</ArticleId></ArticleIdList></Reference><Reference><Citation>Yardeni T., Fine R., Joshi Y., Gradus-Pery T., Kozer N., Reichenstein I., Yanowski E., Nevo S., Weiss-Tishler H., Eisenberg-Bord M., et al. High content image analysis reveals function of miR-124 upstream of Vimentin in regulating motor neuron mitochondria. Sci. Rep. 2018;8:59. doi: 10.1038/s41598-017-17878-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17878-x</ArticleId><ArticleId IdType="pmc">PMC5758812</ArticleId><ArticleId IdType="pubmed">29311649</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell A.P., Wada S., Vergani L., Hock M.B., Lamon S., L&#xe9;ger B., Ushida T., Cartoni R., Wadley G.D., Hespel P., et al. Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol. Dis. 2013;49:107&#x2013;117. doi: 10.1016/j.nbd.2012.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.08.015</ArticleId><ArticleId IdType="pubmed">22975021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi S., Zucca S., Pandini C., Diamanti L., Bordoni M., Sproviero D., Arigoni M., Olivero M., Pansarasa O., Ceroni M., et al. Long non-coding and coding RNAs characterization in Peripheral Blood Mononuclear Cells and Spinal Cord from Amyotrophic Lateral Sclerosis patients. Sci. Rep. 2018;8:2378. doi: 10.1038/s41598-018-20679-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-20679-5</ArticleId><ArticleId IdType="pmc">PMC5799454</ArticleId><ArticleId IdType="pubmed">29402919</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley J., Clarke B.E., Patani R. The Interplay of RNA Binding Proteins, Oxidative Stress and Mitochondrial Dysfunction in ALS. Antioxidants. 2021;10:552. doi: 10.3390/antiox10040552.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10040552</ArticleId><ArticleId IdType="pmc">PMC8066094</ArticleId><ArticleId IdType="pubmed">33918215</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone L., Drexler H.C.A., Wang J., Tripathi P., Distler T., Heisterkamp P., Anderson E.N., Kour S., Moraiti A., Maharana S., et al. FUS pathology in ALS is linked to alterations in multiple ALS-associated proteins and rescued by drugs stimulating autophagy. Acta Neuropathol. 2019;138:67&#x2013;84. doi: 10.1007/s00401-019-01998-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01998-x</ArticleId><ArticleId IdType="pmc">PMC6570784</ArticleId><ArticleId IdType="pubmed">30937520</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordet T., Buisson B., Michaud M., Drouot C., Gal&#xe9;a P., Delaage P., Akentieva N.P., Evers A.S., Covey D.F., Ostuni M.A., et al. Identification andcharacterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 2007;322:709&#x2013;720. doi: 10.1124/jpet.107.123000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.107.123000</ArticleId><ArticleId IdType="pubmed">17496168</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunyach C., Michaud M., Arnoux T., Bernard-Marissal N., Aebischer J., Latyszenok V., Gouarn&#xe9; C., Raoul C., Pruss R.M., Bordet T., et al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology. 2012;62:2346&#x2013;2352. doi: 10.1016/j.neuropharm.2012.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2012.02.013</ArticleId><ArticleId IdType="pubmed">22369784</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T., Lacomblez L., Abitbol J.L., Ludolph A., Mora J.S., Robberecht W., Shaw P.J., Pruss R.M., Cuvier V., Meininger V., et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol. 2014;21:529&#x2013;536. doi: 10.1111/ene.12344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12344</ArticleId><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J., Fancelli D., Wong M., Niedzwiecki M., Ballarini M., Plyte S., Chang Q. GNX-4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis. Front. Cell. Neurosci. 2014;8:433. doi: 10.3389/fncel.2014.00433.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00433</ArticleId><ArticleId IdType="pmc">PMC4271619</ArticleId><ArticleId IdType="pubmed">25565966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono Y., Tanaka H., Takata M., Nagahara Y., Noda Y., Tsuruma K., Shimazawa M., Hozumi I., Hara H. SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models. Neurosci. Lett. 2014;559:174&#x2013;178. doi: 10.1016/j.neulet.2013.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.12.005</ArticleId><ArticleId IdType="pubmed">24334165</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R., Pioro E., Myers K., Sirdofsky M., Goslin K., Meekins G., Yu H., Wymer J., Cudkowicz M., Macklin E.A., et al. Enhanced bulbar function in amyotrophic lateral sclerosis: The nuedexta treatment trial. Neurotherapeutics. 2017;14:762&#x2013;772. doi: 10.1007/s13311-016-0508-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0508-5</ArticleId><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor C.P., Traynelis S.F., Siffert J., Pope L.E., Matsumoto R.R. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta&#xae;) clinical use. Pharmacol. Ther. 2016;164:170&#x2013;182. doi: 10.1016/j.pharmthera.2016.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2016.04.010</ArticleId><ArticleId IdType="pubmed">27139517</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y., Li M., Li J.C., Wei E.Q. Edaravone protects PC12 cells from ischemic-like injury via attenuating the damage to mitochondria. J. Zhejiang Univ. Sci. B. 2006;7:749&#x2013;756. doi: 10.1631/jzus.2006.B0749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1631/jzus.2006.B0749</ArticleId><ArticleId IdType="pmc">PMC1559792</ArticleId><ArticleId IdType="pubmed">16909478</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group. Edaravone (MCI-186) ALS 19 Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M., Ciotti C., Cohen-Tannoudji M., Biferi M.G. Gene Therapy for ALS-A Perspective. Int. J. Mol. Sci. 2019;20:4388. doi: 10.3390/ijms20184388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184388</ArticleId><ArticleId IdType="pmc">PMC6771059</ArticleId><ArticleId IdType="pubmed">31500113</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M., Pradat P.F., Querin G., Biferi M.G. Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy. J. Neuromuscul. Dis. 2021;8:25&#x2013;38. doi: 10.3233/JND-200531.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-200531</ArticleId><ArticleId IdType="pmc">PMC7902976</ArticleId><ArticleId IdType="pubmed">33074186</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A., Cole T., Wegener A.J., Tomassy G.S., Setnicka A., Farley B.J., Schoch K.M., Hoye M.L., Shabsovich M., Sun L., et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Investig. 2018;128:3558&#x2013;3567. doi: 10.1172/JCI99081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT03626012  A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis.  [(accessed on 4 September 2021)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT03626012.</Citation></Reference><Reference><Citation>Corrales L., Glickman L.H., McWhirter S.M., Kanne D.B., Sivick K.E., Katibah G.E., Woo S.R., Lemmens E., Banda T., Leong J.J., et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015;11:1018&#x2013;1030. doi: 10.1016/j.celrep.2015.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.04.031</ArticleId><ArticleId IdType="pmc">PMC4440852</ArticleId><ArticleId IdType="pubmed">25959818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanjulu J.M., Pesiridis G.S., Yang J., Concha N., Singhaus R., Zhang S.Y., Tran J.L., Moore P., Lehmann S., Eberl H.C., et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564:439&#x2013;443. doi: 10.1038/s41586-018-0705-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0705-y</ArticleId><ArticleId IdType="pubmed">30405246</ArticleId></ArticleIdList></Reference><Reference><Citation>Haag S.M., Gulen M.F., Reymond L., Gibelin A., Abrami L., Decout A., Heymann M., van der Goot F.G., Turcatti G., Behrendt R., et al. Targeting STING with covalent small-molecule inhibitors. Nature. 2018;559:269&#x2013;273. doi: 10.1038/s41586-018-0287-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0287-8</ArticleId><ArticleId IdType="pubmed">29973723</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>